L. Delgado

Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Lon Smith, Omar Laterza, Robert H Pierce, 2015, Clinical Cancer Research.

A phase 1 dose-escalation study of anti-HER3 monoclonal antibody LJM716 in combination with trastuzumab in patients with HER2-overexpressing metastatic breast or gastric cancer.

J. Baselga, D. Juric, J. Schellens, 2014 .

Final results of a translational phase l study assessing a QOD schedule of the potent AKT inhibitor MK-2206 incorporating predictive, pharmacodynamic (PD), and functional imaging biomarkers.

A. Tolcher, N. Tunariu, A. Patnaik, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers

Martin O. Leach, Nina Tunariu, Robert A. Beckman, 2014, Clinical Cancer Research.

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.

David Olmos, A. Tolcher, K. Papadopoulos, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors.

A. Tolcher, A. Patnaik, M. Garrett, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract #3604: A phase I single-rising dose study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of an oral akt inhibitor in healthy male volunteers

J. Chodakewitz, J. Wagner, M. Trucksis, 2009 .

A phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer, or HER2-overexpressing metastatic breast or gastric cancer.

J. Baselga, Y. Bang, D. Juric, 2014 .